Docetaxel or abiraterone in addition to androgen deprivation therapy in metastatic castration-sensitive prostate cancer

被引:3
作者
Bilgin, Burak [1 ]
Sendur, Mehmet A. N. [1 ]
Hizal, Mutlu [1 ]
Akinci, Muhammed Bulent [1 ]
Dede, Didem Sener [1 ]
Yalcin, Bulent [1 ]
机构
[1] Yildirim Beyazit Univ, Fac Med, Dept Med Oncol, TR-06800 Ankara, Turkey
关键词
abiraterone; androgen deprivation therapy; docetaxel; prostate cancer;
D O I
10.2217/fon-2017-0270
中图分类号
R73 [肿瘤学];
学科分类号
100214 [肿瘤学];
摘要
引用
收藏
页码:1911 / 1913
页数:3
相关论文
共 8 条
[1]
[Anonymous], N ENGL J MED
[2]
EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer [J].
Cornford, Philip ;
Bellmunt, Joaquim ;
Bolla, Michel ;
Briers, Erik ;
De Santis, Maria ;
Gross, Tobias ;
Henry, Ann M. ;
Joniau, Steven ;
Lam, Thomas B. ;
Mason, Malcolm D. ;
van der Poel, Henk G. ;
van der Kwast, Theo H. ;
Rouviere, Olivier ;
Wiegel, Thomas ;
Mottet, Nicolas .
EUROPEAN UROLOGY, 2017, 71 (04) :630-642
[3]
Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer [J].
Fizazi, Karim ;
NamPhuong Tran ;
Fein, Luis ;
Matsubara, Nobuaki ;
Rodriguez-Antolin, Alfredo ;
Alekseev, Boris Y. ;
Ozguroglu, Mustafa ;
Ye, Dingwei ;
Feyerabend, Susan ;
Protheroe, Andrew ;
De Porre, Peter ;
Kheoh, Thian ;
Park, Youn C. ;
Todd, Mary B. ;
Chi, Kim N. .
NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (04) :352-360
[4]
Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: Data from Southwest Oncology Group trial 9346 (INT-0162) [J].
Hussain, Maha ;
Tangen, Catherine M. ;
Higano, Celestia ;
Schelhammer, Paul F. ;
Faulkner, James ;
Crawford, E. David ;
Wilding, George ;
Akdas, Atif ;
Small, Eric J. ;
Donnelly, Bryan ;
MacVicar, Gary ;
Raghavan, Derek .
JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (24) :3984-3990
[5]
Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial [J].
James, Nicholas D. ;
Sydes, Matthew R. ;
Clarke, Noel W. ;
Mason, Malcolm D. ;
Dearnaley, David P. ;
Spears, Melissa R. ;
Ritchie, Alastair W. S. ;
Parker, Christopher C. ;
Russell, J. Martin ;
Attard, Gerhardt ;
de Bono, Johann ;
Cross, William ;
Jones, Rob J. ;
Thalmann, George ;
Amos, Claire ;
Matheson, David ;
Millman, Robin ;
Alzouebi, Mymoona ;
Beesley, Sharon ;
Birtle, Alison J. ;
Brock, Susannah ;
Cathomas, Richard ;
Chakraborti, Prabir ;
Chowdhury, Simon ;
Cook, Audrey ;
Elliott, Tony ;
Gale, Joanna ;
Gibbs, Stephanie ;
Graham, John D. ;
Hetherington, John ;
Hughes, Robert ;
Laing, Robert ;
McKinna, Fiona ;
McLaren, Duncan B. ;
O'Sullivan, Joe M. ;
Parikh, Omi ;
Peedell, Clive ;
Protheroe, Andrew ;
Robinson, Angus J. ;
Srihari, Narayanan ;
Srinivasan, Rajaguru ;
Staffurth, John ;
Sundar, Santhanam ;
Tolan, Shaun ;
Tsang, David ;
Wagstaff, John ;
Parmar, Mahesh K. B. .
LANCET, 2016, 387 (10024) :1163-1177
[6]
Redefining clinically significant castration levels in patients with prostate cancer receiving continuous androgen deprivation therapy [J].
Morote, Juan ;
Orsola, Anna ;
Planas, Jacques ;
Trilla, Enrique ;
Raventos, Carles X. ;
Cecchini, Lluis ;
Catalan, Roberto .
JOURNAL OF UROLOGY, 2007, 178 (04) :1290-1295
[7]
Cancer Statistics, 2014 [J].
Siegel, Rebecca ;
Ma, Jiemin ;
Zou, Zhaohui ;
Jemal, Ahmedin .
CA-A CANCER JOURNAL FOR CLINICIANS, 2014, 64 (01) :9-29
[8]
Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer [J].
Sweeney, Christopher J. ;
Chen, Yu-Hui ;
Carducci, Michael ;
Liu, Glenn ;
Jarrard, David F. ;
Eisenberger, Mario ;
Wong, Yu-Ning ;
Hahn, Noah ;
Kohli, Manish ;
Cooney, Matthew M. ;
Dreicer, Robert ;
Vogelzang, Nicholas J. ;
Picus, Joel ;
Shevrin, Daniel ;
Hussain, Maha ;
Garcia, Jorge A. ;
DiPaola, Robert S. .
NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (08) :737-746